FIT Biotech Oy
Company release February 14, 2018 at 6.00 pm EET
FIT Biotech Ltd’s own equity negative in the end of January – Fit Biotech Ltd’s own equity to positive with the draw down of a second tranche of financing
The Company’s own equity including additions according to the Companies Act as of January 31, 2018 was 67,200 euro negative. The Board of Directors has taken immediate actions to turn the equity positive.
The second tranche of Alpha Blue financing, 500,000 euro, has been received today. A separate company release has been published today. The equity including additions according to Companies Act is positive as of today.
FIT BIOTECH OY
Board of Directors
For further information:
Chief Executive Officer Erkki Pekkarinen
Tel: +358 44 027 0080
E-mail: erkki.pekkarinen@fitbiotech.com
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
DISTRIBUTION:
Nasdaq Helsinki
Principal media
